Search

everythinglearnresearchcommunity

for

Search:↓

Switching from oral to topical dutasteride can cause shedding due to changes in DHT levels, and it's recommended to overlap both treatments to minimize this effect. Topical dutasteride may cause scalp irritation, and the user is considering dutasteride mesotherapy as an alternative.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Topical melatonin was found to significantly increase hair density and decrease scalp conditions like seborrheic dermatitis. The user is considering using it alongside finasteride and oral minoxidil for treating hair loss and scalp health.

DHT Itch and its link to balding, with various treatments such as finasteride being discussed. Members shared their experiences of scalp itch before and after taking 5AR inhibitors, and potential underlying causes such as seborrheic dermatitis were discussed.

A user with mild psoriasis on the scalp is using finasteride, topical minoxidil, and dermarolling for hair loss but plans to stop minoxidil on the crown due to psoriasis aggravation. Suggestions include switching to a lipid-based minoxidil, using Ketoconazole shampoo, or trying oral minoxidil.

The conversation discusses whether a longtime NW7 scalp has vellus hairs under a microscope or is completely smooth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.

A user is concerned about using Alpicort, which contains Prednisolone and Salicylic Acid, for male pattern baldness. They are unsure if it will help or worsen their condition and are seeking advice.

Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A 25-year-old is experiencing chronic telogen effluvium (TE) and androgenetic alopecia (AGA) after surgery, using finasteride, red light therapy, and supplements, and considering oral minoxidil despite heart concerns. They are unsure whether to start minoxidil before or after an upcoming surgery, which may trigger another hair shed.

The user has been using dutasteride, lymecycline, betamethasone, and minoxidil for hair loss but struggles with eczema and dry skin. They feel hopeless as no treatments or moisturizers have helped, and they are concerned about their appearance due to their soft facial features.

The conversation discusses struggles with diffuse thinning and hair loss treatments, including the use of dutasteride, minoxidil, and finasteride, with limited success. The original poster regrets having a hair transplant at 21 due to weak donor hair and ongoing thinning.

The user experienced severe hair loss, itchy scalp, and skin issues after trying no-shampoo, and wonders if it's male pattern baldness or an immune issue. They have a history of eczema, dermatitis, and jock itch, and have tried various treatments like coconut oil, peppermint, pumpkin seed, and onion.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The user is using minoxidil, finasteride, dermarolling, and other treatments for hair regrowth, showing promising results in the temple area. Despite some skepticism, there is optimism about potential improvement.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Managing seborrheic dermatitis using ketoconazole shampoo, Nizoral, and oils like MCT and coconut oil. The user considers shaving their head and consulting a dermatologist.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

A 20-year-old is experiencing severe diffuse thinning and shedding despite using oral minoxidil for 12 months and dutasteride for 8 months, after previously trying finasteride. They are frustrated with the lack of improvement and considering trying RU58841.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The conversation is about managing an itchy, flaky scalp, possibly due to psoriasis, and the use of a hydrating conditioner to address dryness. The user is concerned about using conditioner due to experiencing telogen effluvium.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

Isotretinoin may cause hair loss by increasing DHT through a precursor androgen, DHEAS. Treatments like topical antiandrogens (RU58841, pyrilutamide) and drugs increasing PPAR-y expression (pioglitazone) might prevent this hair loss.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.